Full history for every metric is available with a Kvantra account
Khiron Life Sciences Corp. (KHRN.V)
Key financial summary
Financials in CAD| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | ||
|---|---|---|---|---|---|---|---|
| Total revenue | CAD m | - | - | - | 10 | 8 | 13 |
| Operating profit | CAD m | -22 | |||||
| Net profit | CAD m | - | - | - | -36 | -24 | -33 |
| EPS reported | CAD | -0.20 | |||||
| Operating cashflow per share | CAD | -0.13 | |||||
| Capex per share | CAD | 0.01 | |||||
| FCF per share | CAD | -0.14 | |||||
| Free cash flow | CAD m | -23 | |||||
| Net debt | CAD m | -7 | |||||
| Book value equity | CAD m | 33 | |||||
| Book value per share | CAD | 0.20 | |||||
| Number of shares | m | 164.52 | |||||
| DPS (TTM paid) | CAD | 0.00 |
Financial summary
Financials in CAD| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | ||
|---|---|---|---|---|---|---|---|
| Value | |||||||
| P/E TTM | x | - | |||||
| P/B LTM | x | 1.04 | |||||
| P/S LTM | x | 2.70 | |||||
| P/FCF LTM | x | -1.53 | |||||
| EV/EBITDA LTM | x | -1.31 | |||||
| EV/Sales LTM | x | 2.18 | |||||
| Earnings Yield LTM | % | -95.89% | |||||
| FCF Yield | % | -65.44% | |||||
| Quality | |||||||
| ROE | % | -99.40% | |||||
| ROIC | % | -61.04% | |||||
| Operating margin | % | -174.52% | |||||
| Gross margin | % | 22.47% | |||||
| FCF/Sales | % | -176.70% | |||||
| Growth and momentum | |||||||
| EPS Growth YoY | % | - | |||||
| Sales Growth YoY | % | +59.60% | |||||
| Net Income Growth YoY | % | - | |||||
| FCF Growth | % | - | |||||
| Operating Profit Growth | % | - | |||||
| Dividend and capital structure | |||||||
| Dividend Yield | % | 0.00% | |||||
| Dividend Growth | % | 0.00% | |||||
| Payout Ratio | % | 0.00% | |||||
| FCF/Debt | x | -10.15 | |||||
| Net Debt/EBITDA | x | 0.32 | |||||
| EBIT/Net interest | x | -50.18 | |||||
| Net debt/market cap | % | -19.38% | |||||
| Net debt/Equity | x | -0.20 | |||||
| Gross debt/equity | x | 0.07 | |||||
Company overview
Khiron Life Sciences Corp. is an integrated enterprise focusing on medical and cannabis solutions across Latin America and Europe. Its operations are structured into Health Services, Medical Cannabis Products, and Wellbeing Products segments. The company's primary activities include the cultivation, production, distribution, and international export of medical cannabis, encompassing both tetrahydrocannabinol (THC) and cannabidiol (CBD). Complementing this, Khiron manages a network of health centers and satellite clinics, operating under the ILANS and Zerenia brands, with specific Zerenia clinics established in Medellin and Peru. Furthermore, it develops CBD-infused cosmeceutical products marketed under the Kuida brand. Khiron Life Sciences Corp. was founded in 2012 and maintains its headquarters in Vancouver, Canada.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Khiron Life Sciences Corp. (KHRN.V)
Khiron Life Sciences Corp. is an integrated enterprise focusing on medical and cannabis solutions across Latin America and Europe. Its operations are structured into Health Services, Medical Cannabis Products, and Wellbeing Products segments. The company's primary activities include the cultivation, production, distribution, and international export of medical cannabis, encompassing both tetrahydrocannabinol (THC) and cannabidiol (CBD). Complementing this, Khiron manages a network of health centers and satellite clinics, operating under the ILANS and Zerenia brands, with specific Zerenia clinics established in Medellin and Peru. Furthermore, it develops CBD-infused cosmeceutical products marketed under the Kuida brand. Khiron Life Sciences Corp. was founded in 2012 and maintains its headquarters in Vancouver, Canada.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free